Abbott Labs (ABT) is Downgraded by Morgan Stanley to Equal-Weight

Abbott Labs (ABT) is Downgraded by Morgan Stanley to Equal-Weight , according to the research report released to the investors. Earlier the firm had a rating of Overweight on the company shares. The shares recommendation by the Brokerage Firm was released on Jan-4-2016.

Abbott Laboratories is up 10.82% in the last 3-month period. Year-to-Date the stock performance stands at 1.87%.The company shares have rallied 0.82% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $51.74 and the one year low was seen on Sep 28, 2015. The 50-Day Moving Average price is $45.09 and the 200 Day Moving Average price is recorded at $45.97.

Abbott Laboratories (NYSE:ABT) has lost 0.42% during the past week and dropped 0.86% in the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.41% and the outperformance increases to 1.46% for the last 4 weeks.

Shares of Abbott Laboratories (NYSE:ABT) ended Thursday session in red amid volatile trading. The shares closed down 0.36 points or 0.8% at $44.91 with 4,192,372 shares getting traded. Post opening the session at $45.11, the shares hit an intraday low of $44.9 and an intraday high of $45.495 and the price vacillated in this range throughout the day. The company has a market cap of $66,993 million and the number of outstanding shares have been calculated to be 1,491,719,900 shares. The 52-week high of Abbott Laboratories (NYSE:ABT) is $51.74 and the 52-week low is $39.

Currently the company Insiders own 0.25% of Abbott Laboratories shares according to the proxy statements. Institutional Investors own 68.74% of Abbott Laboratories shares. During last six month period, the net percent change held by insiders has seen a change of -8.46%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange,The director officer (Chairman and CEO) of Abbott Laboratories, White Miles D sold 438,000 shares at $46.02 on December 16, 2015. The Insider selling transaction had a total value worth of $20,156,760. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Companys business segments include established pharmaceutical products, which include gastroenterology products, womens health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines; diagnostic products, which include a range of diagnostic systems and tests manufactured, marketed and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians offices, government agencies, alternate-care testing sites and plasma protein therapeutic companies; nutritional products, which include a range of pediatric and adult nutritional products manufactured, marketed and sold worldwide, and vascular products, which include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease manufactured, marketed and sold across the world.